Common and Differentiated Representations Between Social Exclusion and Social Separation

NCT ID: NCT05920707

Last Updated: 2023-06-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-20
• Study Completion Date: 2023-10-01

Brief Summary

Explore the shared or separated neural mechanisms of social exclusion and social segregation and compare differential effects of AVP and OXT on these social interaction function.

Detailed Description

A large body of research has shown that there are differences in the neural representation between social exclusion and social segregation, but the results are inconsistent, and the exploration of the neural basis is still insufficient. In addition, there are two mainstream theoretical explanations for these differences, namely the construction-level theory and the emotion-based theory, but there is no consistent theoretical model yet. Therefore, further exploration is necessary to confirm the cognitive and neural mechanisms underlying the differences between social exclusion and social segregation, and to attempt to reveal the theoretical explanations for these differences. In this project, the investigators propose to perform behavioral and functional magnetic resonance imaging (fMRI) techniques to examine the shared or separate neural mechanisms of social exclusion and social segregation (exp 1: social exclusion; exp 2: social separation) and investigate the modulatory effects of OXT/AVP on them (PLC/24IU OXT/20IU AVP).

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Intranasal Oxytocin

Administer oxytocin (24 IU) intranasally.

Group Type: ACTIVE_COMPARATOR

Intranasal Oxytocin

Intervention Type: DRUG

Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.

Intranasal Arginine Vasopressin

Administer Arginine Vasopressin (20 IU) intranasally.

Group Type: ACTIVE_COMPARATOR

Intranasal Arginine Vasopressin

Intervention Type: DRUG

Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.

Intranasal placebo

Administer placebo intranasally.

Group Type: PLACEBO_COMPARATOR

Intranasal placebo

Intervention Type: DRUG

Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.

Intranasal nothing (control)

Control condition

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Intranasal Oxytocin

Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.

Intervention Type: DRUG

Intranasal Arginine Vasopressin

Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.

Intervention Type: DRUG

Intranasal placebo

Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy subjects;

2. Without any past or present psychiatric or neurological disorders;

3. Without any current psychotherapeutic medication.

Exclusion Criteria

1. With any past or present psychiatric or neurological disorders;

2. With any current psychotherapeutic medication.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Electronic Science and Technology of China

OTHER

Sponsor Role: lead

Responsible Party

Weihua Zhao

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Siying Wang, Dr

Role: STUDY_CHAIR

University of Electronic Science and Technology of China

Locations

University of Electronic Science and Technology of China(UESTC)

Chengdu, Sichuan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Keith M Kendrick, Dr

Role: CONTACT

k.kendrick.uestc@gmail.com

+86-28-61830811

Weihua Zhao, Dr

Role: CONTACT

zarazhao@uestc.edu.cn

+8618780247797

Other Identifiers

UESTC-neuSCAN-93

Identifier Type: -

Identifier Source: org_study_id